9th Edition Drug Patents In Canada

$499.00

SKU: PHP10498 Category:

Description

Report Code: PHP10498. May, 2010. Toronto, ON

ARTICLE I

Ground Breaking Decisions: How the Landscape Has Changed for 2010

Donald M. Cameron
Partner
Cameron MacKendrick LLP

Mark Edward Davis
Partner
Heenan Blaikie LLP

ARTICLE II

Sound Prediction of Utility

David Reive
Partner
Dimock Stratton LLP

ARTICLE III

Beating the Wrap: Examining the Use of File Histories in Canadian Patent Litigation

Barbara J. Murchie
Partner
Bennett Jones LLP

Kristina E. Milbourn
Bennett Jones LLP

ARTICLE IV

Nanopharmaceuticals

Raj Bawa, M.S., PhD
Patent Agent, Bawa Biotechnology Consulting LLC
Ashburn (Virginia, USA)
Adjunct Associate Professor, Rensselaer Polytechnic Institute
Troy (New York, USA)
Senior Scientist, SynerGene Therapeutics Inc.
Potomac (Maryland, USA)

ARTICLE V

A Modern Regulator for a Changing Industry

Barbara Ouellet
Executive Director
Patented Medicine Prices Review Board

ARTICLE VI

Settling Pharma Patent Cases: When To, How To and Obstacles To

Andrew Bernstein
Partner
Torys LLP

ARTICLE VII

Subsequent Entry Biologics

Adrienne Blanchard
Partner
Gowlings LLP

ARTICLE VIII

SEBs: An Industry Update

Veera Rastogi
Vice President, Law
Janssen-Ortho Inc.

ARTICLE IX

South of the Border: A Year in Review

Janet I. Cord, Esq.
Partner
Ladas & Parry LLP

ARTICLE X

Strategies in Pharma Patent Litigation

Gunars A. Gaikis
Partner
Smart & Biggar/Fetherstonhaugh

Andrew E. Mandlsohn
Jordan D. Scopa
Jayda S. Sutton

ARTICLE XI

Canadian Duty of Good Faith in Patent Prosecution

Michael E. Charles
Partner
Bereskin & Parr LLP

Angela Furlanetto
Partner
Dimock Stratton LLP

ARTICLE XII

U.S. Patent Law Inequitable Conduct

Daniel Di Napoli
Partner
Kaye Scholer LLP